Literature DB >> 12234875

Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis.

S H Marshall1, C J Donskey, R Hutton-Thomas, R A Salata, L B Rice.   

Abstract

Resistance to linezolid has been associated with a G2576U mutation in domain V of the 23S rRNA. We analyzed nine clinical isolates of linezolid-resistant enterococci and showed a clear association between the number of 23S rRNA genes containing this mutation and the level of linezolid resistance expressed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234875      PMCID: PMC128780          DOI: 10.1128/AAC.46.10.3334-3336.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.

Authors:  R D Gonzales; P C Schreckenberger; M B Graham; S Kelkar; K DenBesten; J P Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Authors:  S Tsiodras; H S Gold; G Sakoulas; G M Eliopoulos; C Wennersten; L Venkataraman; R C Moellering; M J Ferraro
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

3.  Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.

Authors:  J Prystowsky; F Siddiqui; J Chosay; D L Shinabarger; J Millichap; L R Peterson; G A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  A polyclonal outbreak of predominantly VanB vancomycin-resistant enterococci in northeast Ohio. Northeast Ohio Vancomycin-Resistant Enterococcus Surveillance Program.

Authors:  C J Donskey; J R Schreiber; M R Jacobs; R Shekar; R A Salata; S Gordon; C C Whalen; F Smith; L B Rice
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

5.  Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center.

Authors:  P Kloss; L Xiong; D L Shinabarger; A S Mankin
Journal:  J Mol Biol       Date:  1999-11-19       Impact factor: 5.469

6.  Diversity of domain V of 23S rRNA gene sequence in different Enterococcus species.

Authors:  S Tsiodras; H S Gold; E P Coakley; C Wennersten; R C Moellering; G M Eliopoulos
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

7.  Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.

Authors:  D L Shinabarger; K R Marotti; R W Murray; A H Lin; E P Melchior; S M Swaney; D S Dunyak; W F Demyan; J M Buysse
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

8.  Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate.

Authors:  L L Carias; S D Rudin; C J Donskey; L B Rice
Journal:  J Bacteriol       Date:  1998-09       Impact factor: 3.490

  8 in total
  76 in total

Review 1.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci.

Authors:  Alistair Sinclair; Catherine Arnold; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

3.  Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.

Authors:  Issam I Raad; Hend A Hanna; Ray Y Hachem; Tanya Dvorak; Rebecca B Arbuckle; Gassan Chaiban; Louis B Rice
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.

Authors:  Katherine S Long; Christian Munck; Theis M B Andersen; Maria A Schaub; Sven N Hobbie; Erik C Böttger; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

Review 5.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

6.  Molecular detection of linezolid resistance in Enterococcus faecium and Enterococcus faecalis by use of 5' nuclease real-time PCR compared to a modified classical approach.

Authors:  Guido Werner; Birgit Strommenger; Ingo Klare; Wolfgang Witte
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

7.  Heterogeneous macrolide resistance and gene conversion in the pneumococcus.

Authors:  Nicole Wolter; Anthony M Smith; David J Farrell; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

8.  Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus.

Authors:  Nicole Wolter; Anthony M Smith; David J Farrell; William Schaffner; Matthew Moore; Cynthia G Whitney; James H Jorgensen; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

9.  Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center.

Authors:  Thomas E Dobbs; Mukesh Patel; Ken B Waites; Stephen A Moser; Alan M Stamm; Craig J Hoesley
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

10.  Tedizolid susceptibility in linezolid- and vancomycin-resistant Enterococcus faecium isolates.

Authors:  E-M Klupp; A Both; C Belmar Campos; H Büttner; C König; M Christopeit; M Christner; M Aepfelbacher; H Rohde
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-15       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.